Market Cap N/A
Revenue (ttm) 18.51M
Net Income (ttm) -59.04M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 460
Avg Vol 4,358
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 73%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; an...

Phone: 888 321 5212
Address:
6272 West 91st Avenue, Westminster, United States
Latest News on TLSIW
TriSalus Life Sciences Proposes Public Offering

Feb 19, 2026, 4:01 PM EST - 7 weeks ago

TriSalus Life Sciences Proposes Public Offering


TriSalus Reports Q1 2024 Financial Results and Business Update

May 15, 2024, 8:00 AM EDT - 2 years ago

TriSalus Reports Q1 2024 Financial Results and Business Update